<p>美国市场表现强劲，过去一周上涨 3.4%，过去一年上涨 35%，预计年收益增长 16%。在这样一个繁荣的市场中，识别具有强大增长潜力的股票通常需要超越知名公司，关注那些可能不在每位投资者视野中的股票。虽然 “便士股票” 是一个较老的术语，但仍然相关，因为它们通常代表较小或较新的公司，当其财务健康良好时，可能会提供意想不到的价值和稳定性。</p>
<h3>美国十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.3869</td>
<td>$62.22M</td>
<td>✅ 3 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.33</td>
<td>$378.59M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.7401</td>
<td>$84.55M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Information Services Group (III)</td>
<td>$3.11</td>
<td>$194.03M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Niagen Bioscience (NAGE)</td>
<td>$4.74</td>
<td>$376.36M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LifeVantage (LFVN)</td>
<td>$4.35</td>
<td>$52.95M</td>
<td>✅ 4 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Village Farms International (VFF)</td>
<td>$2.88</td>
<td>$307.33M</td>
<td>✅ 5 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>SIGA Technologies (SIGA)</td>
<td>$7.80</td>
<td>$328.13M</td>
<td>✅ 2 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Marine Petroleum Trust (MARP.S)</td>
<td>$5.00</td>
<td>$10M</td>
<td>✅ 2 ⚠️ 4 查看分析 </td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国便士股票筛选器的 349 只股票的完整列表。</p>
<p>让我们从我们的专业筛选器中发现一些宝藏。</p>
<h2>Telos (TLS)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Telos Corporation 及其子公司在美国和国际上提供网络、云和企业安全解决方案，市值约为 3.2526 亿美元。</p>
<p><strong>运营：</strong> 该公司通过其安全网络部门产生收入，金额为 1521 万美元，以及其安全解决方案部门，贡献 14960 万美元。</p>
<p><strong>市值：</strong> 3.2526 亿美元</p>
<p>Telos Corporation 市值为 3.2526 亿美元，尽管显示出显著的收入增长，但仍处于亏损状态，2025 年净亏损为 3655 万美元。尽管如此，该公司无债务，短期资产超过短期和长期负债。最近的发展包括扩展 TSA PreCheck 注册服务，并为其 Xacta Cyber GRC 平台获得 FedRAMP High 授权，增强其风险管理能力。Telos 的股票回购计划反映了对其估值的信心，因为其交易价格显著低于估计的公允价值，尽管存在内部人士抛售的担忧。</p>
<ul>
<li>点击这里通过我们的详细财务健康报告发现 Telos 的细微差别。</li>
<li>通过我们的详细增长报告评估 Telos 的未来收益预期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cf8637cb-0cc5-4c04-9e00-f13f14bb852e/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cf8637cb-0cc5-4c04-9e00-f13f14bb852e/chart/debt-equity-history-analysis"/></p>
<p>截至 2026 年 4 月 TLS 债务与股本历史及分析</p>
<h2>InflaRx (IFRX)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> InflaRx N.V.是一家临床阶段的生物制药公司，专注于在德国和美国发现和开发 C5a 抑制剂技术，市值为 8241 万美元。</p>
<p><strong>运营：</strong> InflaRx 主要通过其制药部门产生收入，金额为 3 万欧元。</p>
<p><strong>市值：</strong> 8241 万美元</p>
<p>InflaRx 市值为 8241 万美元，是一家尚未产生收入的生物制药公司，专注于 C5a 抑制剂技术。该公司最近的体外研究结果突显了 izicopan 在药物相互作用方面的低风险，增强了其药理特征。然而，InflaRx 在财务稳定性方面面临挑战，审计师对其持续经营能力表示怀疑。尽管针对脓疱性坏死性筋膜炎的 vilobelimab 的第三阶段试验显示出一些有希望的结果，但由于无效的担忧而提前终止。该公司无债务，并且在当前条件下有超过一年的现金流。</p>
<ul>
<li>点击这里通过我们的资产负债表健康报告深入了解 InflaRx 的表现。</li>
<li>通过我们的公司收益预期报告获取对 InflaRx 前景和预期表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/15298cd0-d408-4bf2-904a-9edef263d494/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/15298cd0-d408-4bf2-904a-9edef263d494/chart/debt-equity-history-analysis"/></p>
<p>截至 2026 年 4 月 IFRX 债务与股本历史及分析</p>
<h2>Endava (DAVA)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Endava plc 及其子公司在北美、欧洲、英国及国际上提供技术服务，市值为 2.3462 亿美元。</p>
<p><strong>运营：</strong> 该公司通过其计算机服务部门产生 7439 万英镑的收入。</p>
<p><strong>市值：</strong> 2.3462 亿美元</p>
<p>Endava 市值为 2.3462 亿美元，面临挑战，因为它仍处于亏损状态，过去五年损失不断增加。尽管与同行相比交易价格合理，并保持令人满意的债务水平，但预计其收益将以每年 98.6% 的速度显著增长。最近的指导显示 2026 财年的收入略有下降，而战略合作伙伴关系旨在通过 Dava.Flow™增强 AI 原生交付能力。该公司还完成了重大股票回购，减少了 13.59% 的流通股，这可能在持续的运营改善中对股东价值产生积极影响。</p>
<ul>
<li>点击这里深入了解 Endava 的具体情况，通过我们的资产负债表健康报告。</li>
<li>通过查看我们的增长报告获取对 Endava 未来方向的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a31bb721-eaae-48a2-abe6-f764585ca399/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a31bb721-eaae-48a2-abe6-f764585ca399/chart/debt-equity-history-analysis"/></p>
<p>截至 2026 年 4 月 DAVA 债务与股本历史及分析</p>
<h2>关键要点</h2>
<ul>
<li>点击这里开始探索其余的 346 只美国便士股票。</li>
<li>寻找其他投资？寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3>估值是复杂的，但我们在这里为您简化。</h3>
<p>通过我们的详细分析，发现 Endava 是否可能被低估或高估，分析内容包括 <strong>公允价值估计、潜在风险、股息、内部交易和财务状况。</strong></p>
<p>获取免费分析</p>

IFRX

DAVA

乐信集团

MAPS

<p>美国市场在过去一周上涨了 3.4%，在过去一年中上涨了 35%，预计年收益增长将达到 16%。这种环境鼓励投资者探索低价股，这些股票可能提供意想不到的价值。值得注意的低价股包括 WM Tech、乐信集团和 Telos Corporation，尽管这些公司尚未盈利，但由于其无债务状态和收入增长，显示出潜力。InflaRx 是一家临床阶段的生物制药公司，面临财务稳定性挑战，但仍保持无债务。Endava 虽然未盈利，但预计将实现显著的收益增长，并已进行股票回购以提升股东价值</p>

<p>The United States market has shown robust performance, rising 3.4% over the last week and 35% over the past year, with earnings projected to grow by 16% annually. In such a thriving market, identifying stocks with strong potential for growth often involves looking beyond well-known names to those that might not be on every investor's radar. Penny stocks, though an older term, remain relevant as they often represent smaller or newer companies that could offer surprising value and stability when backed by solid financial health.</p>
<div class="lb-trans"><p>美国市场表现强劲，过去一周上涨 3.4%，过去一年上涨 35%，预计年收益增长 16%。在这样一个繁荣的市场中，识别具有强大增长潜力的股票通常需要超越知名公司，关注那些可能不在每位投资者视野中的股票。虽然 “便士股票” 是一个较老的术语，但仍然相关，因为它们通常代表较小或较新的公司，当其财务健康良好时，可能会提供意想不到的价值和稳定性。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美国十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.3869</td>
<td>$62.22M</td>
<td>✅ 3 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.33</td>
<td>$378.59M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.7401</td>
<td>$84.55M</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Information Services Group (III)</td>
<td>$3.11</td>
<td>$194.03M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Niagen Bioscience (NAGE)</td>
<td>$4.74</td>
<td>$376.36M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>LifeVantage (LFVN)</td>
<td>$4.35</td>
<td>$52.95M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Village Farms International (VFF)</td>
<td>$2.88</td>
<td>$307.33M</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>SIGA Technologies (SIGA)</td>
<td>$7.80</td>
<td>$328.13M</td>
<td>✅ 2 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Marine Petroleum Trust (MARP.S)</td>
<td>$5.00</td>
<td>$10M</td>
<td>✅ 2 ⚠️ 4 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.3869</td>
<td>$62.22M</td>
<td>✅ 3 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.33</td>
<td>$378.59M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.7401</td>
<td>$84.55M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Information Services Group (III)</td>
<td>$3.11</td>
<td>$194.03M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Niagen Bioscience (NAGE)</td>
<td>$4.74</td>
<td>$376.36M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LifeVantage (LFVN)</td>
<td>$4.35</td>
<td>$52.95M</td>
<td>✅ 4 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Village Farms International (VFF)</td>
<td>$2.88</td>
<td>$307.33M</td>
<td>✅ 5 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>SIGA Technologies (SIGA)</td>
<td>$7.80</td>
<td>$328.13M</td>
<td>✅ 2 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Marine Petroleum Trust (MARP.S)</td>
<td>$5.00</td>
<td>$10M</td>
<td>✅ 2 ⚠️ 4 查看分析 </td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 349 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国便士股票筛选器的 349 只股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>让我们从我们的专业筛选器中发现一些宝藏。</p>
</div><h2>Telos (TLS)</h2>
<div class="lb-trans"><h2>Telos (TLS)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Telos Corporation, along with its subsidiaries, offers cyber, cloud, and enterprise security solutions both in the United States and internationally, with a market cap of approximately $325.26 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Telos Corporation 及其子公司在美国和国际上提供网络、云和企业安全解决方案，市值约为 3.2526 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue through its Secure Networks segment, which accounts for $15.21 million, and its Security Solutions segment, contributing $149.6 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司通过其安全网络部门产生收入，金额为 1521 万美元，以及其安全解决方案部门，贡献 14960 万美元。</p>
</div><p><strong>Market Cap:</strong> $325.26M</p>
<div class="lb-trans"><p><strong>市值：</strong> 3.2526 亿美元</p>
</div><p>Telos Corporation, with a market cap of US$325.26 million, has shown significant revenue growth but remains unprofitable, posting a net loss of US$36.55 million for 2025. Despite this, the company is debt-free and its short-term assets exceed both short and long-term liabilities. Recent developments include the expansion of TSA PreCheck enrollment services and achieving FedRAMP High authorization for its Xacta Cyber GRC platform, enhancing its risk management capabilities. Telos's share buyback program reflects confidence in its valuation as it trades significantly below estimated fair value despite insider selling concerns.</p>
<div class="lb-trans"><p>Telos Corporation 市值为 3.2526 亿美元，尽管显示出显著的收入增长，但仍处于亏损状态，2025 年净亏损为 3655 万美元。尽管如此，该公司无债务，短期资产超过短期和长期负债。最近的发展包括扩展 TSA PreCheck 注册服务，并为其 Xacta Cyber GRC 平台获得 FedRAMP High 授权，增强其风险管理能力。Telos 的股票回购计划反映了对其估值的信心，因为其交易价格显著低于估计的公允价值，尽管存在内部人士抛售的担忧。</p>
</div><ul>
<li>Click here to discover the nuances of Telos with our detailed analytical financial health report.</li>
<li>Assess Telos' future earnings estimates with our detailed growth reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里通过我们的详细财务健康报告发现 Telos 的细微差别。</li>
<li>通过我们的详细增长报告评估 Telos 的未来收益预期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cf8637cb-0cc5-4c04-9e00-f13f14bb852e/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/cf8637cb-0cc5-4c04-9e00-f13f14bb852e/chart/debt-equity-history-analysis"/></p>
<p>TLS Debt to Equity History and Analysis as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月 TLS 债务与股本历史及分析</p>
</div><h2>InflaRx (IFRX)</h2>
<div class="lb-trans"><h2>InflaRx (IFRX)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing C5a inhibitor technology in Germany and the United States, with a market cap of $82.41 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> InflaRx N.V.是一家临床阶段的生物制药公司，专注于在德国和美国发现和开发 C5a 抑制剂技术，市值为 8241 万美元。</p>
</div><p><strong>Operations:</strong> InflaRx generates its revenue primarily from its Pharmaceuticals segment, which amounts to €0.03 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> InflaRx 主要通过其制药部门产生收入，金额为 3 万欧元。</p>
</div><p><strong>Market Cap:</strong> $82.41M</p>
<div class="lb-trans"><p><strong>市值：</strong> 8241 万美元</p>
</div><p>InflaRx, with a market cap of $82.41 million, is a pre-revenue biopharmaceutical company focusing on C5a inhibitor technology. The company's recent in vitro findings highlight izicopan's low risk for drug-drug interactions, enhancing its pharmacological profile. However, InflaRx faces challenges with its financial stability as auditors have expressed doubts about its ability to continue as a going concern. While the Phase 3 trial for vilobelimab in pyoderma gangrenosum showed some promising results, it was terminated early due to futility concerns. The company remains debt-free and has sufficient cash runway for over a year if current conditions persist.</p>
<div class="lb-trans"><p>InflaRx 市值为 8241 万美元，是一家尚未产生收入的生物制药公司，专注于 C5a 抑制剂技术。该公司最近的体外研究结果突显了 izicopan 在药物相互作用方面的低风险，增强了其药理特征。然而，InflaRx 在财务稳定性方面面临挑战，审计师对其持续经营能力表示怀疑。尽管针对脓疱性坏死性筋膜炎的 vilobelimab 的第三阶段试验显示出一些有希望的结果，但由于无效的担忧而提前终止。该公司无债务，并且在当前条件下有超过一年的现金流。</p>
</div><ul>
<li>Get an in-depth perspective on InflaRx's performance by reading our balance sheet health report here.</li>
<li>Gain insights into InflaRx's outlook and expected performance with our report on the company's earnings estimates.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里通过我们的资产负债表健康报告深入了解 InflaRx 的表现。</li>
<li>通过我们的公司收益预期报告获取对 InflaRx 前景和预期表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/15298cd0-d408-4bf2-904a-9edef263d494/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/15298cd0-d408-4bf2-904a-9edef263d494/chart/debt-equity-history-analysis"/></p>
<p>IFRX Debt to Equity History and Analysis as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月 IFRX 债务与股本历史及分析</p>
</div><h2>Endava (DAVA)</h2>
<div class="lb-trans"><h2>Endava (DAVA)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Endava plc, along with its subsidiaries, offers technology services across North America, Europe, the United Kingdom, and internationally, with a market cap of $234.62 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Endava plc 及其子公司在北美、欧洲、英国及国际上提供技术服务，市值为 2.3462 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates £743.90 million in revenue from its computer services segment.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司通过其计算机服务部门产生 7439 万英镑的收入。</p>
</div><p><strong>Market Cap:</strong> $234.62M</p>
<div class="lb-trans"><p><strong>市值：</strong> 2.3462 亿美元</p>
</div><p>Endava, with a market cap of US$234.62 million, is navigating challenges as it remains unprofitable with increasing losses over the past five years. Despite trading at a good value compared to peers and maintaining satisfactory debt levels, its earnings are forecast to grow significantly at 98.6% per year. Recent guidance indicates a slight revenue decline for fiscal 2026, while strategic partnerships aim to enhance AI-native delivery capabilities through Dava.Flow™?. The company has also completed significant share buybacks, reducing outstanding shares by 13.59%, which may influence shareholder value positively amidst ongoing operational improvements.</p>
<div class="lb-trans"><p>Endava 市值为 2.3462 亿美元，面临挑战，因为它仍处于亏损状态，过去五年损失不断增加。尽管与同行相比交易价格合理，并保持令人满意的债务水平，但预计其收益将以每年 98.6% 的速度显著增长。最近的指导显示 2026 财年的收入略有下降，而战略合作伙伴关系旨在通过 Dava.Flow™增强 AI 原生交付能力。该公司还完成了重大股票回购，减少了 13.59% 的流通股，这可能在持续的运营改善中对股东价值产生积极影响。</p>
</div><ul>
<li>Dive into the specifics of Endava here with our thorough balance sheet health report.</li>
<li>Gain insights into Endava's future direction by reviewing our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解 Endava 的具体情况，通过我们的资产负债表健康报告。</li>
<li>通过查看我们的增长报告获取对 Endava 未来方向的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a31bb721-eaae-48a2-abe6-f764585ca399/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/a31bb721-eaae-48a2-abe6-f764585ca399/chart/debt-equity-history-analysis"/></p>
<p>DAVA Debt to Equity History and Analysis as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月 DAVA 债务与股本历史及分析</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>关键要点</h2>
</div><ul>
<li>Click through to start exploring the rest of the 346 US Penny Stocks now.</li>
<li>Seeking Other Investments? Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里开始探索其余的 346 只美国便士股票。</li>
<li>寻找其他投资？寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值是复杂的，但我们在这里为您简化。</h3>
</div><p>Discover if Endava might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通过我们的详细分析，发现 Endava 是否可能被低估或高估，分析内容包括 <strong>公允价值估计、潜在风险、股息、内部交易和财务状况。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>获取免费分析</p>
</div>

2026 年 4 月值得关注的具有潜在增长机会的便士股票